Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Young gastrointestinal angle: How to prepare and submit a job application.

Nakov R, Peck-Radosavljevic M.

United European Gastroenterol J. 2018 Feb;6(1):160-161. doi: 10.1177/2050640618754756. Epub 2018 Jan 22. No abstract available.

2.

Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.

Blackwell K, Gascon P, Jones CM, Nixon A, Krendyukov A, Nakov R, Li Y, Harbeck N.

Ann Oncol. 2017 Sep 1;28(9):2272-2277. doi: 10.1093/annonc/mdx303.

3.

Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.

Harbeck N, Gascon P, Jones CM, Nixon A, Krendyukov A, Nakov R, Li Y, Blackwell K.

Future Oncol. 2017 Jul;13(16):1385-1393. doi: 10.2217/fon-2017-0041. Epub 2017 Apr 28.

5.

Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.

Harbeck N, Lipatov O, Frolova M, Udovitsa D, Topuzov E, Ganea-Motan DE, Nakov R, Singh P, Rudy A, Blackwell K.

Future Oncol. 2016 Jun;12(11):1359-67. doi: 10.2217/fon-2016-0016. Epub 2016 Mar 29.

6.

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.

Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, Harbeck N.

Ann Oncol. 2015 Sep;26(9):1948-53. doi: 10.1093/annonc/mdv281. Epub 2015 Jun 28.

7.

The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.

Kitas GD, Abreu G, Jedrychowicz-Rosiak K, Miller JL, Nakov R, Panfilov S, Vencovsky J, Wang M, Weinblatt ME, White WB.

J Am Soc Hypertens. 2014 Nov;8(11):780-90. doi: 10.1016/j.jash.2014.08.013. Epub 2014 Sep 4.

PMID:
25455003
8.

Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.

Mitrovic V, Seferovic P, Dodic S, Krotin M, Neskovic A, Dickstein K, de Voogd H, Böcker C, Ziegler D, Godes M, Nakov R, Essers H, Verboom C, Hocher B.

Circ Heart Fail. 2009 Nov;2(6):523-31. doi: 10.1161/CIRCHEARTFAILURE.108.798389. Epub 2009 Sep 24.

9.

Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.

Holzgreve H, Nakov R, Beck K, Janka HU.

Am J Hypertens. 2003 May;16(5 Pt 1):381-6.

PMID:
12745200
10.

Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.

Breddin HK, Kadziola Z, Scully M, Nakov R, Misselwitz F, Kakkar VV.

Thromb Haemost. 2003 Feb;89(2):272-7.

PMID:
12574806
11.
12.

Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.

Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R.

Br J Haematol. 2002 Sep;118(4):1137-42.

PMID:
12199798
13.

Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension.

Nakov R, Pfarr E, Eberle S; HEAT Investigators.

Am J Hypertens. 2002 Jul;15(7 Pt 1):583-9.

PMID:
12118903
14.

Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.

Kakkar VV, Hoppenstead DA, Fareed J, Kadziola Z, Scully M, Nakov R, Breddin HK.

Blood. 2002 Mar 15;99(6):1965-70.

15.

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety.

N Engl J Med. 2001 Mar 1;344(9):626-31.

16.

Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension.

Cifková R, Nakov R, Novozámská E, Hejl Z, Petrzílková Z, Poledne R, Stávek P, Compagnone D.

J Hum Hypertens. 2000 Jun;14(6):347-54.

PMID:
10878692
18.
19.

Effects of botulinum A toxin on presynaptic modulation of evoked transmitter release.

Nakov R, Habermann E, Hertting G, Wurster S, Allgaier C.

Eur J Pharmacol. 1989 May 2;164(1):45-53.

PMID:
2568939
20.

Staurosporine counteracts the phorbol ester-induced enhancement of neurotransmitter release in hippocampus.

Daschmann B, Allgaier C, Nakov R, Hertting G.

Arch Int Pharmacodyn Ther. 1988 Nov-Dec;296:232-45.

PMID:
2907278
21.

[Effect of adrenergic substances on the capacity of human spermatozoa to penetrate cervical mucus in vitro].

Nakov R, Ovcharov R.

Eksp Med Morfol. 1987;26(1):13-6. Bulgarian. No abstract available.

PMID:
3595493
22.

[Effect of methylxanthines on the motility and velocity of human spermatozoa].

Nakov R, Stanislavov R, Ovcharov R.

Akush Ginekol (Sofiia). 1987;26(1):59-64. Bulgarian. No abstract available.

PMID:
3592114
23.

[cAMP levels in human spermatozoa after exposure to methylxanthines].

Nakov R, Vlasovska M.

Eksp Med Morfol. 1987;26(4):7-10. Bulgarian. No abstract available.

PMID:
2833388

Supplemental Content

Support Center